［1］国家食品药品监督管理局.抗菌药物药代动力学／药效学研究技术指导原则.北京，2017.

［2］ TEXTORIS J，WIRAMUS S，MARTIN C，et al. Antibiotic therapy in patients with septic shock. Eur J Anaesthesiol，2011，28（5）：318-324.

［3］ GONÇALVES-PEREIRA J，PÓVOA P. Antibiotics in critically ill patients：a systematic review of the pharmacokinetics of β-lactams. Critical Care，2011，15（5）：R206.

［4］ BRINK AJ，RICHARDS GA，SCHILLACK V，et al.Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis.Int J Antimicrob Agents，2009，33（5）：432-436.

［5］ JARURATANASIRIKUL S，SUDSAI T.Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion.J Antimicrob Chemother，2009，63（3）：560-563.

［6］ JARURATANASIRIKUL S，SRIWIRIYAJAN S，PUNYO J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother，2005，49（4）：1337-1339.

［7］ LAMOTH F，BUCLIN T，CSAJKA C，et al. Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies. Antimicrob Agents Chemother，2009，53（2）：785-787.

［8］ WATANABE A，FUJIMURA S，KIKUCHI T，et al. Evaluation of dosing designs of carbapenems for severe respiratory infection using Monte Carlo simulation. J Infect Chemother，2007，13（5）：332-340.

［9］ JARURATANASIRIKUL S，LIMAPIEHAT T，JULLANGKOON M，et al. Pharmacodynamies of mempenem in critically ill patients with febrile neutropenia and bacteraemia. Int J Antimierob Agents，2011，38（3）：231-236.

［10］ LI X，WANG L，ZHANG XJ，et al. Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model. Antimicrob Agents Chemother，2014，58（11）：6773-6781.